Lukas Gerstweiler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lukas Gerstweiler has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Jingxiu Bi
School of Chemical Engineering, Faculty of Science, Engineering and Technology, University of Adelaide, Adelaide 5005, Australia
6 shared publicationsJagan Billakanti
Global Life Sciences Solutions Australia Pty Ltd. Parramatta New South Wales Australia
4 shared publications- Anton Peter Jacob Middelberg
Division of Research and Innovation The University of Adelaide Adelaide South Australia Australia
3 shared publications Hong Luo
Protein Expression Facility The University of Queensland Brisbane Australia
3 shared publicationsYanhao Gu
School of Chemical Engineering Adelaide University Adelaide Australia
3 shared publicationsYanyan Ma
State Key Laboratory of Biochemical Engineering, Key Laboratory of Biopharmaceutical Preparation and Delivery (CAS), Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China
3 shared publications
Latest Publications
- 29 January 2026
- Published by Wiley in Current Protocols
- Vol. 6 (2) , e70309
Rapid, Scalable, and Cost‐Effective Manufacturing of Uniform Non‐Enveloped, Tag‐Free Virus‐Like Particles
Virus‐like particles (VLPs) are widely recognized as safe and versatile nanostructures with broad applications in vaccine development, gene delivery, and nanotechnology, but their production typically requires time‐consuming procedures, incurs high costs, and yields products of limited purity. This article outlines a rapid, scalable, and cost‐effective method for producing high‐quality VLPs using the VP1s capsid protein from murine polyomavirus. The procedure comprises four principal stages: expression of the capsid protein in Escherichia coli , extraction and stabilization of the protein, purification to yield high‐quality capsomeres, and controlled in vitro assembly of VLPs. Compared with conventional protocols that rely on in vivo assembly and labor‐intensive purification procedures, such as ultracentrifugation‐ or affinity tag‐based methods, the described approach provides a streamlined and rapid workflow that avoids affinity tags, achieves consistently high yields, and enables precise regulation of assembly conditions, resulting in a scalable and highly cost‐efficient strategy for VLP production within 5 days. © 2026 Wiley Periodicals LLC. This article was corrected on 13 February 2026. See the end of the full text for details. Basic Protocol 1 : Expression and preparation of polyomavirus VP1 protein in E. coli Basic Protocol 2 : Polymomavirus VP1 purification Basic Protocol 3 : VP1 assembly Basic Protocol 4 : Quality control
- 29 January 2026
- Published by Wiley in Current Protocols
- Vol. 6 (2) , e70309
Rapid, Scalable, and Cost‐Effective Manufacturing of Uniform Non‐Enveloped, Tag‐Free Virus‐Like Particles
Virus‐like particles (VLPs) are widely recognized as safe and versatile nanostructures with broad applications in vaccine development, gene delivery, and nanotechnology, but their production typically requires time‐consuming procedures, incurs high costs, and yields products of limited purity. This article outlines a rapid, scalable, and cost‐effective method for producing high‐quality VLPs using the VP1s capsid protein from murine polyomavirus. The procedure comprises four principal stages: expression of the capsid protein in Escherichia coli , extraction and stabilization of the protein, purification to yield high‐quality capsomeres, and controlled in vitro assembly of VLPs. Compared with conventional protocols that rely on in vivo assembly and labor‐intensive purification procedures, such as ultracentrifugation‐ or affinity tag‐based methods, the described approach provides a streamlined and rapid workflow that avoids affinity tags, achieves consistently high yields, and enables precise regulation of assembly conditions, resulting in a scalable and highly cost‐efficient strategy for VLP production within 5 days. © 2026 Wiley Periodicals LLC. This article was corrected on 13 February 2026. See the end of the full text for details. Basic Protocol 1 : Expression and preparation of polyomavirus VP1 protein in E. coli Basic Protocol 2 : Polymomavirus VP1 purification Basic Protocol 3 : VP1 assembly Basic Protocol 4 : Quality control
- Top Cited PapersOpen Access
- 20 January 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 306
Process and analytical strategies for the safe production of mRNA vaccines and therapeutics
The production of high-purity mRNA drug substances by in vitro transcription utilizing T7 RNA polymerase can be challenging due to the formation of product related impurities. These include double-stranded RNA, fragmented mRNA, and uncapped transcripts. This review examines the known mechanisms underlying the formation of the major mRNA impurities during in vitro transcription (IVT), their biological impact and strategies for their mitigation. Some companies have utilised engineered T7 RNA polymerases and optimized transcription conditions to improve mRNA purity. There is a growing focus on refining upstream and downstream processes to improve mRNA purity. The current analytical approaches for impurity detection and quantification are reviewed. These range from immunological assays to advanced chromatographic and sequencing technologies. Continued innovation is needed to develop the next generation of high-throughput, cost-efficient analytical methods for quantifying mRNA impurities. Together improved transcription, purification and analysis enable the manufacture of safe efficacious mRNA for vaccines and therapeutics.
- 20 January 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 306
Top Cited PapersOpen AccessProcess and analytical strategies for the safe production of mRNA vaccines and therapeutics
The production of high-purity mRNA drug substances by in vitro transcription utilizing T7 RNA polymerase can be challenging due to the formation of product related impurities. These include double-stranded RNA, fragmented mRNA, and uncapped transcripts. This review examines the known mechanisms underlying the formation of the major mRNA impurities during in vitro transcription (IVT), their biological impact and strategies for their mitigation. Some companies have utilised engineered T7 RNA polymerases and optimized transcription conditions to improve mRNA purity. There is a growing focus on refining upstream and downstream processes to improve mRNA purity. The current analytical approaches for impurity detection and quantification are reviewed. These range from immunological assays to advanced chromatographic and sequencing technologies. Continued innovation is needed to develop the next generation of high-throughput, cost-efficient analytical methods for quantifying mRNA impurities. Together improved transcription, purification and analysis enable the manufacture of safe efficacious mRNA for vaccines and therapeutics.
- Open Access
- 16 September 2025
- Published by Elsevier in Biotechnology Advances
- Vol. 85, 108715
Microfluidics in biomanufacturing process development
- 16 September 2025
- Published by Elsevier in Biotechnology Advances
- Vol. 85, 108715
Open AccessMicrofluidics in biomanufacturing process development
- Open Access
- 7 August 2025
- Published by Elsevier in Journal of Chromatography A
- Vol. 1760, 466274
Column ageing of agarose-based chromatography in industrial lactoferrin purification
- 7 August 2025
- Published by Elsevier in Journal of Chromatography A
- Vol. 1760, 466274
Open AccessColumn ageing of agarose-based chromatography in industrial lactoferrin purification
- 5 February 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 303, 140511
Corrigendum to “Investigating the stability of chimeric murine polyomavirus VP1 Capsomeres via molecular dynamics simulations and experimental analysis” [Int. J. Biol. Macromol., volume 286, January 2025, 138372]
- 5 February 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 303, 140511
Corrigendum to “Investigating the stability of chimeric murine polyomavirus VP1 Capsomeres via molecular dynamics simulations and experimental analysis” [Int. J. Biol. Macromol., volume 286, January 2025, 138372]
- Open Access
- 4 December 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 286, 138372
Investigating the stability of chimeric murine polyomavirus VP1 Capsomeres via molecular dynamics simulations and experimental analysis
- 4 December 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 286, 138372
Open AccessInvestigating the stability of chimeric murine polyomavirus VP1 Capsomeres via molecular dynamics simulations and experimental analysis
- Open Access
- 2 October 2023
- Published by Elsevier in Journal of Chromatography A
- Vol. 1710, 464428
Model based process optimization of an industrial chromatographic process for separation of lactoferrin from bovine milk
- 2 October 2023
- Published by Elsevier in Journal of Chromatography A
- Vol. 1710, 464428
Open AccessModel based process optimization of an industrial chromatographic process for separation of lactoferrin from bovine milk
- 12 July 2022
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 119 (8)
Cover Image, Volume 119, Number 8, August 2022
- 12 July 2022
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 119 (8)
Cover Image, Volume 119, Number 8, August 2022